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Abstract
This article presents an overview of the changes that are taking place 
within the public and private health innovation systems in India includ-
ing delivery of medical care, pharmaceutical products, medical devices, 
and Indian traditional medicine. The nature of the flaws that exist in the 
health innovation system is pinpointed. The response by the government, 
the health, technology and medical institutions, and the evolving indus-
try is addressed on a national level. The article also discusses how the 
alignment of policies and institutions was developed within the scope of 
national health innovation systems, and how the government and the in-
dustry are dealing with the challenges to integrate health system, industry, 
and social policy development processes.
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Introduction
This article analyses the Indian health innova-
tion system focusing on different actors involved 
in healthcare delivery, pharmaceuticals, medi-
cal devices, and traditional medicine. Compared 
to the first four decades of post-independence, 
the Indian health innovation system today is sig-
nificantly different in terms of spread of market 
governance institutions for healthcare promo-
tion. While, the last two decades emulated the 
trajectory of capitalist globalization, there has 
also been a countervailing power emerging in In-
dia through the resistance being put up by social 
movements (“health as a right”). State regulation 
and social control have emerged in India as major 
issues in health innovation policy, together with 
improvements in the supply of critical inputs for 
the organization and management of innovation 
activities in pharmaceuticals, diagnostics, medi-
cal devices, and traditional healthcare. 
Health innovation contains most of the ele-
ments of change in healthcare. It is inherently 
complex to implement and operate, as it involves 
a combination of technological and organiza-
tional renewal within an environment featuring 
a diversity of stakeholders. It covers a wide range 
of changes in the design of services, products, 
and production processes (technology element); 
new or altered ways in organizing or adminis-
tering activities (organization element); new or 
improved ways of interacting with other orga-
nizations and knowledge bases (system inter-
action element); new worldviews, rationalities, 
missions, and strategies (conceptual element). 
Changes in the health innovation system often 
involved the introduction of interrelated chang-
es in technological, organizational, and institu-
tional elements of healthcare. Many innovations 
are also systemic in nature, since they emerge 
from, and must address the complex interplay 
between political, administrative, technological, 
institutional, and legal issues. In this context the 
present paper undertakes a preliminary analy-
sis of the performance of the health innovation 
system with due attention to its major segments, 
locates the nature of failures, and highlights the 
response from the major actors involved. In the 
subsequent sections, the article provides a brief 
overview of the components of the health inno-
vation system and the current scenario of health 
innovations in healthcare delivery, pharmaceuti-
cals, medical devices, and indigenous medicine 
in India, before concluding with various chal-
lenges and priorities.
Innovations in the healthcare system 
The 1990s witnessed an intensified spread of 
health markets. Public health was reconfigured 
to focus on a few cost-effective priorities: Disabil-
ity-adjusted life years (DALYs) saved per dollar 
spent provided the criterion for measuring suc-
cess of reforms. During this decade, public health 
focused mainly on programs to reduce infant, 
child, and maternal mortality rates and to control 
malaria, leprosy, tuberculosis, and HIV. The rest 
was left to the private sector. Health became mar-
ket-driven, with the promise of insurance vouch-
ers for the poor. Both health professional educa-
tion and medical research became increasingly 
market-driven, with huge regional and thematic 
imbalances. Innovation and research programs 
started to be driven by international aid.
While it is true that India has much to claim in 
healthcare, much more remains to be done given 
the high infant and maternal mortality rates, fal-
tering immunization coverage, stagnating nutri-
tional status of children, and significant levels 
of mortality from communicable diseases 1. The 
plausible reasons include: meagre allocation in 
the health budget, lack of demand from the poor, 
and persistence of dysfunctional and unrespon-
sive healthcare services due to the spread of un-
regulated markets. Low utilization of rural public 
health services is also due to the unwillingness 
of trained doctors to work in rural areas without 
proper infrastructure. There are also geographic 
and regional disparities in distribution and qual-
ity of healthcare services and social inequalities 
that have impact on health outcomes. 
The latest effort to improve healthcare de-
livery is through National Rural Health Mission 
(NRHM), a system capable of influencing the ar-
chitecture of the state level health systems. The 
NRHM organizes the central government health 
programs in a systematic manner. It calls for re-
form and introduction of architectural innova-
tion in the case of health system(s) to make them 
functional in the states. Figure 1 presents the 
basic characteristics of innovations introduced 
via NRHM.
Another critical component in the planning 
and implementation of the NRHM is the Na-
tional Urban Health Mission (NUHM). Schol-
ars often point out the irony of urban health-
care. Despite the proximity of the urban poor 
to health facilities, their access is severely re-
stricted by the inadequacy of health services. 
Here, most innovations were developed to in-
troduce programming and financing flexibility 
that was accorded by the NRHM and Reproduc-
tive Child Health (RCH). Most of 227 identified 
innovations refer to improving service delivery. 
BUILDING INCLUSIVE HEALTH INNOVATION SYSTEMS S3
Cad. Saúde Pública, Rio de Janeiro, 32 Sup 2:e00045215, 2016
Figure 1
National Rural Health Mission (NRHM): main approaches.
AYUSH: Ayurveda, Yoga, Unani, Siddha and Homeopathy; BRG: Block Resource Group; CHC: Community Health Centre; DRG: District Resource Group;  
IPHS: Indian Public Health Standards; NGO: Nongovernmental Organization; NHSRC: National Health Systems Resource Centre; PHC: Public Health Centre; 
PRI: Panjayati Raj Institutions; SHSRC: State Health Systems Resource Centre. 
Source: the authors from Sundararaman 10.
Innovations are reported from all states, but we 
see a higher number of innovations being im-
plemented in Tamil Nadu, Chhattisgarh, Mad-
hya Pradesh, Andhra Pradesh, and some of the 
North Eastern states. The state of Tamil Nadu 
has a strong public health system, and all the 
innovations implemented were led by the state, 
with no external partner. Analysis also reveals 
contracting-out of health facilities to Nongov-
ernmental Organizations (NGOs). The stimulus 
for such contracting-out at least to the private 
sector in some states appears to be external 
donor support, as in Uttar Pradesh, West Ben-
gal, Madhya Pradesh, and Assam. In contrast, 
contracting out Public Health Centres (PHCs) 
to NGOs is a state-led innovation in Karnataka, 
Arunachal Pradesh, and Meghalaya.
Two key innovations in outsourcing to the 
private sector that have been adopted for rep-
lication by several states are (i) public-private 
partnerships for the delivery of maternity ser-
vices and (ii) emergency transport for obstetric 
referral. The innovation that appears to have 
set the stage for contracting out maternity ser-
vices to the private sector began in Gujarat, 
with several states replicating them. It appears 
that many of the innovations that were scaled 
up for implementation in health systems were 
devoid of adequate evidence about their effec-
tiveness. It should also be noted that almost all 
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innovations are funded through government: na-
tional or state level.
Innovations in pharmaceuticals 
Technological capability-building processes 
have been the focus of policymakers in the Indi-
an pharmaceutical industry since the early 1970s 
with the introduction of new patent legislation 
and the adoption of drug policy (1978). Under the 
Indian Patent Act (1970), the country’s national 
system of innovation was free to develop alter-
nate processes for the drugs that were still under 
product patent protection in developed coun-
tries. During the 1980s several domestic firms 
entered the local market using process tech-
nologies developed both in-house and in public 
research laboratories. 
Table 1 presents process technologies con-
tributed by public research laboratories for com-
pounds manufactured for different diseases. It is 
evident that priority was assigned to Type I life-
style diseases (cancer, obesity, diabetes, cardio-
vascular diseases, and hepatitis), especially dur-
ing 1965-1994 (in the first two phases). In terms 
of degree of originality and novelty pursued, over 
50 new processes were developed during the pe-
riod of 1965-1980 in public labs that benefited 
Indian pharmaceutical firms.
Public laboratories are also engaged in the 
development of new drugs. Some of these drugs 
succeeded in the market with the help of national 
health and family welfare programs. But until the 
early 1990s, domestic companies, mostly of me-
dium scale, lacked resources for product devel-
opment. They started to develop capabilities re-
quired for new processes, formulations, dosages, 
new salts, derivatives, isomers, polymorphs, and 
other “less radical” products to enter the regu-
lated markets of U.S. and Europe. However their 
in-house capabilities were seemingly not devel-
oped enough to give them a competitive edge 
over generic companies originating from Israel 
and Europe. 
Indian pharmaceutical firms have obtained 
approval from the U.S. Food and Drug Admin-
istration (FDA) for more than 450 different ac-
tive pharmaceutical ingredients (APIs). India can 
now claim to possess a rich vendor base with 3.75 
drug master files (DMFs) per molecule being ap-
proved by the US regulatory body 2. This implies 
that the manufacturers can legitimately export 
the respective molecule to the United States. 
Compared to contract manufacturing, the 
option of export of generics to the regulated mar-
kets of U.S. and Europe is a better route for large 
Indian pharmaceutical companies upgrading 
capabilities related to development of advanced 
elements of processes, analogue product, and 
formulations. Even now India has only a small 
presence in advanced formulations, accounting 
for just 3% of its total sales. India is also absent 
from non-conventional dosage forms. India has 
just 48 products in specialty generics, which is 
insignificant as the U.S. market is close to 1,250 
products 3. Evidence available from the patent-
ing activity of companies active in the Indian 
pharmaceutical industry shows that the domes-
tic research and development (R&D) directions 
are skewed and tilted in favor of development of 
analogue molecules, new forms of substances, 
dosages, and formulations (Table 2). There is still 
only a small amount of activity of new chemical 
entities (NCEs) 4.
Indian companies are still directing their 
R&D efforts to the area of generics. Basically the 
potential NCEs being developed at home by In-
dian companies have been licensed out to global 
pharmaceutical firms for further development. 
Further, in India too, traditional pharmaceutical 
companies are now shifting their focus to bio-
pharmaceuticals. For example, Dr. Reddys’ Labo-
ratories (DRL) is known to be working on at least 
eight bio-similars for therapeutic use in oncology 
and autoimmune disorders. As far as bio-thera-
peutics is concerned, it does seem to be on the 
radar of Indian pharmaceutical companies in a 
significant way. The Indian industry is achieving 
better breakthroughs on vaccines 5 as the devel-
opment of a variety of vaccines from conjugated 
to combination and recombinant vaccines is on 
the radar of Biocon, Serum Institute, Bharat Se-
rums and Vaccines, and Panacea Biotech. 
In publicly financed innovation, the focus 
earlier was on diseases that were considered na-
tional priorities, in areas where all over the world 
public finance drives innovation (such as con-
traception, tuberculosis, malaria, and filariasis). 
The public sector targeted commercial products 
too, for example in biopharmaceuticals. 
As an alternative to the model of drug dis-
covery in which the incentive comes from the 
use of a strong intellectual property system, a 
new institutional arrangement is also now un-
der experimentation in the form of open source 
drug discovery (OSDD). OSDD is a web-en-
abled interactive platform that will list the cur-
rent design challenges for developing drugs to 
treat drug-resistant tuberculosis, malaria, and 
HIV. It has much potential to involve research-
ers from all over the world in product develop-
ment for the benefit of neglected diseases. The 
first step in the OSDD initiative by the Council 
of Scientific and Industrial Research (CSIR) is 
the launch of an open source website hosting 
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Table 1
Type of process technologies contributed by the Council of Scientific and Industrial Research (CSIR), India.
Type of disease Year Total 
1965-1980 1981-1994 1995-2005
Type I 39 21 7 67
Type II 5 2 3 10
Type III 6 4 2 12
Others (not targeted to any type of disease) 1 1 3 5
Grand total 51 28 15 94
Source: Abrol et al. 4.
Table 2
Indian pharmaceutical patents in U.S. Patent and Trademark Office (USPTO), India.
Nature of patent 1992-1995 1996-1999 2000-2003 2004-2007 Total 
Process patent 11 51 133 195
NDDS patent 18 23 41
NCE patent 3 6 10 19
Method of treatment, dosage, formulation, composition, 
combination & product patent
14 26 102 261 403
New forms of substances 6 63 156 225
Grand total 14 46 240 583 883
NCE: new chemical entities; NDDS: nano drugs delivery system. 
Source: Abrol et al. 4.
information on Mycobacterium tuberculosis, 
the bacterial pathogen that causes tuberculosis. 
This information includes gene sequences, ex-
pression, function, activity, and the response to 
drugs of all tuberculosis proteins as well as host- 
pathogen interactions. 
Innovations in medical devices
India has less than one per cent of the global 
market in medical devices, despite having one-
sixth of the world’s total population and the 
fact that nearly 71% of demand is met through 
imports. This excessive reliance on imports for 
medical devices, which is also a manifestation 
of low technological capability, has implications 
for costs and access. There are approximately 700 
medical device manufacturers in the industry, 
mainly local device makers, focusing on low-val-
ue products such as needles and catheters. Most 
high-value products are often imported. There 
is a need to build an ecosystem that fosters in-
novation, manufacture, and rational utilization 
of these devices.
Broadly there are four types of actors – Gov-
ernment research labs (e.g., Sree Chitra Tirunal 
Institute for Medical Science and Technology 
Services, Trivandrum, Central Scientific Instru-
ments Organisation, Chandigarh), academic in-
stitutions, industrial units in the private sector 
and international collaborative programs with 
multi-disciplinary Indian institutions. Of these, 
Sree Chitra Tirunal Institute for Medical Science 
and Technology (SCTIMST) has a good track re-
cord which has brought a number of products 
into the national market and subsequently into 
the international market. Their most well-known 
products are prosthetic heart valves and blood 
bags. Their main driving principle was import 
substitution as a form of cost reduction and bet-
ter availability, but once these products were 
available there was international interest in their 
use. CSIR laboratories too have introduced inno-
vative products, but faced difficulties in scaling 
up either through commercialization or through 
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public systems uptake. Academic institutions 
have commercialized a number of products. 
One of the major forms of innovation in the 
industry has been the “jugaad” (a “frugal” form 
of innovation) by Punjab and Tamil Nadu small-
scale entrepreneurs. The small scale units gain 
considerable strength from being clustered and 
informally networked. They are also able to draw 
upon tacit knowledge and unstructured experi-
ences from a surprisingly wide area. A more re-
cent development is the emergence of large scale 
innovation establishments that aim to tap Indian 
skills and talents in innovation for internation-
al markets and to take advantage of the huge 
and hitherto untapped Indian market. Leading 
amongst these are GE and Siemens located in 
Bangalore. There are also small start-up techno-
entrepreneur-led companies such as Remidio, 
Embrace, BigTecXcyton, and ReaMetrix in Ban-
galore. There are similar companies in Mumbai 
and Delhi as well. These are very small, very inno-
vative, home-grown companies in the diagnostic 
and/or device space. These are focused on being 
innovative and bringing out low-cost devices for 
the Indian market.
Another major development is academia-dri-
ven international collaboration, such as the Stan-
ford Bio-Design project between IIT Delhi, All 
India Institute of Medical Sciences (AIIMS), and 
Stanford University with the financial support of 
the Department of Biotechnology (DBT). Other 
examples are the Johns Hopkins University colla-
borative programs with substantial USAID sup-
port. A third successful example is the University 
of Oslo, Norwegian Agency for Development and 
Co-operation (NORAD) supported effort at deve-
lopment of health informatics, which features a 
tie-up with the National Health System Resource 
Centre (NHSRC) and an Indian not-for-profit or-
ganization created partly for commercialization. 
A major issue of concern is unfair competi-
tion from international corporations. The Sree 
Chitra Tirunal Institute for Medical Sciences and 
Technology’s initiatives in blood bags for open 
heart surgery, an innovative cost-saving prod-
uct, was held back due to its threat to a multi-
national firm’s interests. Unfair marketing could 
also raise questions of safety and credibility of 
new products and prevent low-cost innovations 
in the market. This is not as much a problem 
with screening/diagnostic devices, but where 
invasive or therapeutic procedures (e.g. cardiac 
stents, implants, or staplers) are concerned, pa-
tients would be more apprehensive about qual-
ity. There is a role for the government in ensuring 
a level playing field for all domestic and interna-
tional players, and the best approach is to en-
sure a transparent quality assurance and regula-
tion system, as well as watchfulness and action 
against monopoly practices. 
Innovations in indigenous medicines
Historically, most innovations in this area were 
at the instance of private sector, especially from 
Bengal and Kerala. The Department of Ayurveda, 
Yoga and Naturopathy, Unani, Siddha and Ho-
moeopathy (AYUSH), a governmental body, was 
created in 1995 with the purpose of developing 
education and research in traditional Indian 
medicine systems. However, the budgetary allo-
cations of the department have remained paltry 
and have never been more than 3% of the total 
government health budget. 
It now appears that a vibrant and highly 
interactive innovation system with greater in-
tegration between actors within and outside 
the country is in the making. To illustrate, Arya 
Vaidya Sala, Kottakkal (AVS), and Pankajakast-
huri signed an agreement with the Tropical Bo-
tanical Garden and Research Institute (TBGRI) 
for medicinal plant research, and Arya Vaidya 
Pharmacy (AVP) received financial help from 
the U.S. National Institutes of Health to de-
velop and consolidate scientific collaboration 
between researchers at the Ayurvedic Trust, 
Coimbatore, and leading U.S. universities. The 
funding is mostly for plant conservation and 
standardization of medicines. Many institutions 
like the Department of Science and Technology 
(DST), Indian Council for Medical Research (IC-
MR), Central Council for Research in Ayurveda 
(CCRA), Technical Information Forecasting and 
Assessment Council (TIFAC), Ministry of Sci-
ence, Department of Bio-technology, Ministry 
of Environment and Forests, etc. are actively in-
volved in the research related to herbal medicine 
and products. Formation of AYUSH, medicinal 
plant boards, TKDL (which aims at making all 
documented information on Ayurveda available 
to patent examiners so as to prevent grant of pat-
ents on non-original inventions) and the Golden 
Triangle Partnership Scheme (GTP) of the DST, 
CSIR, and ICMR collaboration are recent impor-
tant steps in this direction. Nevertheless, the ac-
ademia-industry interface in this sector remains 
low. However, in Kerala, it is found that many 
manufacturing firms encourage postgraduate 
students to undertake their degree projects in 
the firms, which fund the students in process and 
product research 6. 
At present, R&D in Ayurveda, Siddha, and 
Unani focuses on new drug development, in-
novative processes for known drugs, and de-
velopment of plant-based molecules through 
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leads from traditional knowledge-holders 7. The 
innovative approaches in indigenous medicine 
research include ethno-pharmacology, reverse 
pharmacology, systems biology, and personal-
ized approach 8. Various institutions, including 
the ICMR and CSIR, are exploring paths that 
could be cheaper, faster, and more effective. CSIR 
and several public and private partners have just 
concluded a series of clinical trials on herbal 
products of medicinal value generated through 
reverse pharmacology. 
R&D in the Ayurveda industry is mainly con-
centrated on clinical research, process-related 
research, and medicinal plant research. But this 
is very minimal compared to expenditure on 
non-technological innovations like aesthetic 
appearances and new packaging forms. Clinical 
research is aimed at evolving new methods and 
procedures for dealing with acute ailments such 
as cancer, rheumatic arthritis etc. Process-related 
research broadly covers activities like bioactive 
research, standardization, development of new 
products, etc. 5. AVS Kottakkal has recently set up 
a Medicinal Plant Research Centre with a view to-
wards conservation and sustainable cultivation 
of medicinal plants. AVS has research collabora-
tion with many national and international insti-
tutions like the Council of Scientific and Indus-
trial Research (CSIR), International Development 
Research Centre (IDRC), etc. Currently, India has 
national and state medicinal plant boards pro-
moting sustainable cultivation as well as various 
incentive schemes for in-house cultivation and 
ex-situ conservation and research.
Concurrently, firms also concentrate on nu-
traceuticals and cosmetics. Government of India 
also adopted the Good Manufacturing Practices 
(GMP) for ayurvedic units from June 2002; with 
the objective of quality assurance. The industry 
has over 9,000 producers in the country, which 
aims at markets in Africa, Latin America, and 
Southeast Asia.
In general, priority in research has been to 
handle type I lifestyle diseases or neurological 
disorders and brain stimulation. Some work has 
been done on other diseases that are refractory 
to allopathic drugs, e.g., psoriasis, arthritis, and 
bronchial asthma. However, the research priori-
ties in AYUSH Research Councils have often been 
decided on readily available leads from botani-
cal knowledge or community knowledge, rather 
than desired areas of public health needs. To pro-
mote innovations through interactive learning 
and collaborations, AYUSH has started around 
ten clusters of ayurvedic products in different 
parts of the country. Even though the existing 
“reformulative” structure does not support tech-
nological innovations, the possibilities of interac-
tive learning and social innovations are evident 
in the industry.
Concluding remarks: innovation barriers, 
strengths, and priorities
We have shown that interactions, institutions, 
and incentives are characterized by their own na-
tional and regional rigidities specific to the cur-
rent development path in India. Sub-systems of 
health innovation are structured very differently 
in areas of health system development, medical 
devices, health informatics, and pharmaceuti-
cals. Health innovation systems are still working 
in a fragmented way. Market influence on phar-
maceutical innovation has been increasing. In 
different areas, as for example medical devices, 
the patterns of mobilization being followed by 
different actors, ranging from independent pro-
fessionals to hospitals and pharmaceutical firms, 
are guided by strategies that do not converge with 
the interest of the population as a whole. Both 
state and private sectors need to be closely moni-
tored and appropriately regulated.
On the whole it appears that there are several 
barriers to the formation of a vibrant innovation 
system. One of the most important is the inertia 
for interactive learning between different actors 
involved and the lack of coordination of agencies 
acting on different levels of the value chain. Lack 
of synergy between prototype development, 
commercial developers/manufacturers, health 
economists, and social scientists that could as-
sess the costs and social consequences of the 
technology are important gaps that prevent scal-
ing up of technologies. The stronger patent re-
gime along with the power of international cor-
porate agencies resulting in unfair competition 
and uneven playing fields along with inappropri-
ate institutional arrangements for strategic alli-
ances and collaborations pose major challenges 
to health innovation in India. 
Barriers are emerging due to the lack of clear 
protocols and supporting institutions that could 
systematically scrutinize and approve testing 
of new products, especially class II. Protocols 
should not only specifically mandate the mini-
mum required tests, but should include bio-
compatibility guidelines, quality standards, and 
processes by which tests could be registered and 
monitored. Lack of common testing facilities that 
a large number of innovators can access is also a 
barrier both for drugs and for devices. 
Despite the large number of barriers, there 
are also a number of great strengths that can 
be built upon. The first is the culture and prac-
tice of jugaad ‒ the ability to innovate within 
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considerable resource constraints 9. This could 
be complemented with India’s achievements in 
information technology and clinical care. Many 
low-cost innovations continue to occur even 
within existing circumstances, including local 
adaptations and jugaad in health systems and 
service delivery. But even these require sustained 
financial and organizational support, for com-
mercialization, dissemination, standardization, 
and scaling up. Sustained and adequate financ-
ing is required for innovation in high-cost life-
saving equipment and new products as well. 
Another strength is the living traditions of 
Ayurveda, Siddha and Unani, whose potential 
contribution to learning and innovation are yet 
to be fully tapped. There is one type of learning 
where there is a search for better molecules. The 
immense potential for such learning could be ap-
preciated if we recall that over 80% of all modern 
pharmaceuticals are derived from active ingre-
dients found in indigenous remedies that were 
validated on empirical grounds – a process that 
has been ongoing for more than 200 years. An-
other type of learning is the use of procedures 
absorbed from Ayurveda, Siddha and Unani in 
their entirety and context, without searching for 
active ingredients. 
India should utilize the core of academic and 
research institutions which have been engaged in 
healthcare innovation over the last 100 years in 
pharmaceuticals, and over the last 30 to 40 years 
in medical devices, information and communi-
cations technology, and public health institu-
tions. Though many of these were not very suc-
cessful because of barriers discussed earlier, con-
siderable social capital has been built up that can 
now be leveraged. Public policy needs to actively 
promote and welcome those innovations that 
serve the needs of public health policy: increased 
access, quality, and affordability of health care, 
greater health equity, increased responsiveness 
of the system to healthcare needs, autonomy in 
healthcare choices, and above all, improvements 
in the social determinants of healthcare.
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Resumo
O artigo apresenta um panorama das mudanças 
atualmente em curso dentro dos sistemas público e 
privado de inovação em saúde na Índia, incluindo a 
prestação de serviços médicos, produtos farmacêuti-
cos, dispositivos médicos e medicina tradicional in-
diana. É destacada a natureza das falhas que existem 
nos sistemas de inovação em saúde. As respostas do go-
verno, das instituições médicas, de saúde e tecnologia e 
indústrias envolvidas, são abordadas em nível nacio-
nal. O artigo também discute como foi desenvolvido o 
alinhamento de políticas e instituições no escopo dos 
sistemas nacionais de inovação em saúde, e como go-
verno e indústria estão lidando com os desafios para 
integrar o sistema de saúde, a indústria e o desenvolvi-
mento de políticas sociais.
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Resumen
El artículo presenta el panorama de los cambios ac-
tualmente en curso dentro de los sistemas públicos y 
privados de innovación en salud en la India, inclu-
yendo la prestación de servicios médicos, productos 
farmacéuticos, dispositivos médicos y medicina tradi-
cional india. Se destaca la naturaleza de las carencias 
que existen en los sistemas de innovación en salud. Los 
autores abordan la respuesta existente, a nivel nacio-
nal, por parte del gobierno, instituciones médicas y de 
salud y tecnología, y por la industria en este proceso 
de evolución. El artículo también discute cómo se de-
sarrolló la alineación de políticas e instituciones en el 
alcance de los sistemas nacionales de innovación en 
salud, y cómo el gobierno, así como la industria, están 
enfrentando los desafíos que se presentan, con el fin 
de integrar sistema de salud, industria y desarrollo de 
políticas sociales.
Tecnología Biomédica; Sistemas de Salud;  
Desarrollo Sostenible; Innovación
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